Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind

Eli Lilly may not be an expensive stock when you consider its long-run growth prospects.Eli Lilly (LLY -0.92%) stock is up a mammoth 770% in five years. It is trading at new all-time highs in 2024 thanks to the incredible success and popularity of its diabetes and weight loss products, Mounjaro and Zepbound. But with the stock standing at a market capitalization of $850 billion and a mammoth price-to-earnings multiple of 117, you might think it ludicrous to expect it could still be a good buy.Normally, I'd ...